Transcode Therapeutics, Inc., a biotech company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on January 11, 2024, will not undergo review by the commission. The SEC's communication, dated January 16, 2024, was addressed to R. Michael Dudley, CEO of Transcode Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process, and reminded the company of its responsibility for the accuracy and adequacy of disclosures. The SEC provided contact information for Tim Buchmiller for any further questions regarding the matter.

Transcode Therapeutics, Inc., a biotech company, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-1, filed on January 11, 2024, will not undergo review by the commission. The SEC's communication, dated January 16, 2024, was addressed to R. Michael Dudley, CEO of Transcode Therapeutics. The SEC's letter referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process, and reminded the company of its responsibility for the accuracy and adequacy of disclosures. The SEC provided contact information for Tim Buchmiller for any further questions regarding the matter.